BioCentury | Aug 19, 2013
Emerging Company Profile

PxRadia: Ceramide selectivity

...toxicity. PxRadia's 2A2 antibody selectively targets only pathological ceramide-rich domains in damaged cells. In 2010, PxRadia...
...Kolesnick is head of the laboratory of signal transduction at Memorial Sloan-Kettering Cancer Center . PxRadia...
...Sloan-Kettering is eligible for undisclosed royalties and milestones. The company is pursuing post-exposure GI ARS. PxRadia...
BioCentury | Apr 26, 2012
Distillery Therapeutics

Indication: Gastrointestinal disease

...mAb decreased radiation-induced endothelial apoptosis in the intestine and increased survival compared with antibody control. PxRadia Inc.'s...
...Published online April 26, 2012 Work covered by patent and filed patent applications; licensed to PxRadia...
BioCentury | Jan 12, 2012
Strategy

A conversation with Laurie Glimcher

...Inc. Berwyn, Pa. Wilms tumor 1 (WT1) peptide vaccines for the treatment of leukemia 2011 PxRadia Inc....
Items per page:
1 - 3 of 3
BioCentury | Aug 19, 2013
Emerging Company Profile

PxRadia: Ceramide selectivity

...toxicity. PxRadia's 2A2 antibody selectively targets only pathological ceramide-rich domains in damaged cells. In 2010, PxRadia...
...Kolesnick is head of the laboratory of signal transduction at Memorial Sloan-Kettering Cancer Center . PxRadia...
...Sloan-Kettering is eligible for undisclosed royalties and milestones. The company is pursuing post-exposure GI ARS. PxRadia...
BioCentury | Apr 26, 2012
Distillery Therapeutics

Indication: Gastrointestinal disease

...mAb decreased radiation-induced endothelial apoptosis in the intestine and increased survival compared with antibody control. PxRadia Inc.'s...
...Published online April 26, 2012 Work covered by patent and filed patent applications; licensed to PxRadia...
BioCentury | Jan 12, 2012
Strategy

A conversation with Laurie Glimcher

...Inc. Berwyn, Pa. Wilms tumor 1 (WT1) peptide vaccines for the treatment of leukemia 2011 PxRadia Inc....
Items per page:
1 - 3 of 3